Unlock instant, AI-driven research and patent intelligence for your innovation.

Tablet containing finenone and preparation method of tablet

A technology of tablets and tablet cores, applied in the field of tablets containing finerenone and its preparation, to achieve the effects of high stability, stable quality, and good process tolerance

Pending Publication Date: 2021-01-19
REYOUNG PHARMA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are no patents and literatures in China to disclose the prescription and process related to finerenone tablets

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tablet containing finenone and preparation method of tablet
  • Tablet containing finenone and preparation method of tablet
  • Tablet containing finenone and preparation method of tablet

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-4

[0047] In the drug tablet core formulations of Examples 1-4, the particle size of the finerenone micropowder is different, which is used to investigate the influence of the particle size of the finerenone micropowder on the dissolution rate of the drug. The drug tablet core prescription of embodiment 1-4 is as shown in table 1.

[0048] The drug tablet core prescription of table 1 embodiment 1-4

[0049]

[0050] Prepare finerenone-containing tablets according to the above prescription, as follows:

[0051] (1) Finerenone is micronized to the corresponding particle size of each embodiment;

[0052] (2) Add finerenone, povidone K30, and sodium lauryl sulfate after micronization to 150 mg of purified water to prepare a granular solution;

[0053] (3) Put microcrystalline cellulose, pregelatinized starch, and crospovidone into a wet granulator, low-cut and low-stir (low speed 150r / min, shear 1500r / min) for 20min, mix well, add Granule solution, low shear and high stirring (...

Embodiment 5-8

[0063] In the drug tablet core prescription of embodiment 5-8, the type and consumption of filler and disintegrant are different, for investigating the influence of filler and disintegrant on drug disintegration time, the drug tablet core of embodiment 5-8 The prescription and drug disintegration time are shown in Table 3.

[0064] Tablets containing finerenone are prepared as follows:

[0065] (1) Micronize finerenone to a particle size of D50≤35μm, D90≤82μm;

[0066] (2) Add finerenone, povidone K30, and sodium lauryl sulfate after micronization to 200 mg of purified water to prepare a granular solution;

[0067] (3) Put microcrystalline cellulose, pregelatinized starch, and disintegrant (crospovidone or croscarmellose sodium) into the wet granulator, low-cut and low-stir (low speed 150r / min, shear 1500r / min) 20min, mix evenly, add granule solution, low shear and high stir (high speed 300r / min, shear 1500r / min) 10min, carry out granulation;

[0068] (4) the obtained gran...

Embodiment 9-12

[0075] In the drug tablet core prescription of embodiment 9-12, the type of solubilizing agent, dosage and adding method are different, and are used to investigate the influence of solubilizing agent on drug disintegration time, the drug tablet core prescription of embodiment 9-12, adding method of solubilizing agent and drug disintegration time are shown in Table 4.

[0076] Tablets containing finerenone are prepared as follows:

[0077] (1) Micronize finerenone to a particle size of D50≤35μm, D90≤82μm;

[0078] (2) Add finerenone, povidone K30, and solubilizer (sodium lauryl sulfate or poloxamer) after micronization into 170 mg of purified water to prepare a granular solution;

[0079] (3) Put microcrystalline cellulose, pregelatinized starch, crospovidone, and solubilizer (sodium lauryl sulfate) into a wet granulator, low-cut and low-stir (low speed 150r / min, shear Cut at 1500r / min) for 20min, mix evenly, add granule solution, low-cut and high-stir (high speed 300r / min, c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of pharmaceutical preparations, in particular to a tablet containing finenone and a preparation method of the tablet. The tablet containing finenone comprises a medicine tablet core and a coating layer, and the medicine tablet core is prepared from the following raw materials in parts by weight: 5-30 parts of finenone, 85-135 parts of a filler, 5-7 parts of a disintegrating agent, 5-7 parts of an adhesive, 0.3-1 part of a solubilizer and 0.6-1.2 parts of a lubricant; and the coating layer is a water-soluble coating material. The tablet containing the finenone is good in dissolution performance and high in stability, a good dissolution effect can be achieved under all media, and the invention further provides the preparation method of the tabletcontaining the finenone.

Description

Technical field [0001] The invention relates to the technical field of pharmaceutical preparations, and in particular to a finerenone-containing tablet and a preparation method thereof. Background technique [0002] Currently used aldosterone receptor antagonists are spironolactone (first generation), eplerenone (second generation), etc. Large clinical trials have shown that spironolactone and eplerenone can significantly improve the prognosis and survival rate of patients with heart failure, but their selectivity is low and may lead to adverse reactions such as increased blood potassium levels in patients, so they are not used as first-line drugs. Finerenone is a third-generation aldosterone receptor antagonist with the following structural formula: [0003] [0004] Finerenone binds in the ligand-binding domain of MR in a different manner than steroidal mineralocorticoid receptor antagonists and exhibits a high binding rate, with only a concentration of antagonist requ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K9/36A61K31/4375A61K47/38A61K47/36A61P9/04
CPCA61K31/4375A61K9/2054A61K9/2059A61K9/2866A61P9/04
Inventor 苗得足胡清文李荣丽王向华杨书华
Owner REYOUNG PHARMA